NSE · ORCHPHARMA
Orchid Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹238 Cr with net profit ₹31 Cr — a 12.88% net margin, versus -2.81% the period before.
Shareholding
As of 2026-06-30
- Promoter69.84%
- Public8.61%
- FII0.81%
- DII20.75%
33,433 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.33× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #33 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,74,972 Cr | 38.22 | 5.68 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,133 Cr | 214.66 | 3.46 | 11.27% | 14% |
| Lupin Limited | ₹1,12,150 Cr | 70.42 | 5 | 23.76% | 19.4% |
| Zydus Lifesciences Ltd. | ₹1,12,060 Cr | 20.63 | 4.13 | 18.59% | 18.86% |
| Mankind Pharma Limited | ₹1,07,123 Cr | 192.99 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,100 Cr | 344.06 | 18.12 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,353 Cr | 431.09 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,638 Cr | 100.57 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,853 Cr | 545.51 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,734 Cr | 286.55 | 4.9 | 16.66% | 15.65% |
| Orchid Pharma Limited(this company) | ₹5,042 Cr | 211.98 | 3.92 | 2.11% | 2.51% |
AI analysis
AI-generated · google/gemini-2.5-flashOrchid Pharma Limited trades on the Indian markets with a market capitalization of Rs 5308 Cr. The company reported revenue of Rs 949.4 Cr and a net profit of Rs 99.6568 Cr for the year ending Mar 2025. Its 52-week high was Rs 1119.8 and its 52-week low was Rs 480.
Positives
- +The company's profit margin is high at 250.9%.
- +Return on equity (ROE) is 210.6%.
- +The debt-to-equity ratio is low at 0.13.
- +Promoter holding is substantial at 69.8355% as of March 31, 2026.
Negatives
- −Return on capital employed (ROCE) is low at 2.4751%.
- −The dividend yield is 0%.
- −Net profit in Dec 2025 was negative at -Rs 12.61 Cr.
- −The December 2025 quarter reported negative EBITDA of -Rs 1.86 Cr.
- −The company is under LT-ASM and ASM 1 surveillance.
Financial Performance
For the financial year ending March 2025, Orchid Pharma Limited generated a revenue of Rs 949.4 Cr. The annualized revenue growth stood at 12.5%. The company's net profit margin was 250.9%, leading to a profit of Rs 99.6568 Cr for the same period. Earnings per share (EPS) for the year ending Mar 2025 were Rs 19.65.
Profitability & Returns
The company's profit margin was 250.9%. Return on equity (ROE) was 210.6%, while return on capital employed (ROCE) was 2.4751%. The earnings per share (EPS) is reported at Rs 5.35.
Balance Sheet
Orchid Pharma Limited has a debt-to-equity ratio of 0.13, indicating a low level of debt relative to its equity. The book value per share is Rs 253.91.
Ownership & Pledges
As of March 31, 2026, promoters held 69.8355% of the shares. Public shareholding was 9.0463%, while domestic institutional investors (DIIs) held 20.2484%. Foreign institutional investors (FIIs) held 0.8698% of the company's shares. The total number of shareholders was 35118.
Regulatory & Surveillance
Orchid Pharma Limited is under LT-ASM and ASM 1 surveillance measures. No pledges against promoter shareholding were reported as of the latest available data.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.